<DOC>
	<DOCNO>NCT00777179</DOCNO>
	<brief_summary>This study multicenter , randomize , double-blinded , placebo-controlled Phase II study compare vandetanib ( 300mg daily ) plus best supportive care ( BSC ) placebo plus BSC maintenance treatment patient locally advance metastatic NSCLC , receive responded prior platinum-doublet systemic chemotherapy . The primary objective study compare Progression Free Survival ( PFS ) rate 3 month locally advance metastatic NSCLC patient without vandetanib maintenance .</brief_summary>
	<brief_title>Phase II Zactima Maintenance Locally Advanced Metastatic Non-small-cell Lung Carcinoma ( NSCLC ) Following Platinum-doublet Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologic cytologic confirmation locally advance metastatic NSCLC ( IIIbIV ) time original diagnosis . Completion 4 cycle chemotherapy gemcitabine ( 1,000 1250mg/m^2/day day 1 8 ) cisplatin ( 7080mg/m^2/day day 1 ) every 3 week show response , Complete Response ( CR ) , Partial Response ( PR ) stable disease ( SD ) RECIST . WHO PS 01 No prior radiotherapy chest , immunotherapy biologic therapy Mixed small cell non smallcell lung cancer history . Prior treatment EGFR TKIs VEGFR TKIs ( prior treatment cetuximab [ Erbitux ] bevacizumab [ Avastin ] permit . ) Evidence severe uncontrolled systemic disease concurrent condition investigator 's opinion make undesirable patient participate study would jeopardize compliance protocol . Radiation therapy within 4 week start study therapy . Major surgery within 4 week , incomplete heal surgical incision start study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vandetanib , NSCLC , Maintenance , Phase II</keyword>
</DOC>